000023050 001__ 23050
000023050 005__ 20200402210320.0
000023050 0247_ $$2pmid$$apmid:22891248
000023050 0247_ $$2pmc$$apmc:PMC3464581
000023050 0247_ $$2DOI$$a10.1074/jbc.M112.357665
000023050 0247_ $$2WOS$$aWOS:000309654200078
000023050 0247_ $$2altmetric$$aaltmetric:887460
000023050 037__ $$aPreJuSER-23050
000023050 041__ $$aeng
000023050 082__ $$a570
000023050 1001_ $$0P:(DE-HGF)0$$aKroth, H.$$b0
000023050 245__ $$aDiscovery and structure activity relationship of small molecule inhibitors of toxic-ß--amyloid-42 fibril formation
000023050 260__ $$aBethesda, Md.$$bSoc.$$c2012
000023050 300__ $$a34786 - 34800
000023050 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000023050 3367_ $$2DataCite$$aOutput Types/Journal article
000023050 3367_ $$00$$2EndNote$$aJournal Article
000023050 3367_ $$2BibTeX$$aARTICLE
000023050 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000023050 3367_ $$2DRIVER$$aarticle
000023050 440_0 $$03091$$aJournal of Biological Chemistry$$v287$$x0021-9258
000023050 500__ $$aRecord converted from VDB: 12.11.2012
000023050 520__ $$aIncreasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in the pathogenesis of Alzheimer disease. Thus, inhibiting Aβ aggregation, among others, has emerged as a potential therapeutic intervention for this disorder. Herein, we employed 3-aminopyrazole as a key fragment in our design of non-dye compounds capable of interacting with Aβ42 via a donor-acceptor-donor hydrogen bond pattern complementary to that of the β-sheet conformation of Aβ42. The initial design of the compounds was based on connecting two 3-aminopyrazole moieties via a linker to identify suitable scaffold molecules. Additional aryl substitutions on the two 3-aminopyrazole moieties were also explored to enhance π-π stacking/hydrophobic interactions with amino acids of Aβ42. The efficacy of these compounds on inhibiting Aβ fibril formation and toxicity in vitro was assessed using a combination of biophysical techniques and viability assays. Using structure activity relationship data from the in vitro assays, we identified compounds capable of preventing pathological self-assembly of Aβ42 leading to decreased cell toxicity.
000023050 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000023050 536__ $$0G:(DE-Juel1)FUEK505$$aBioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung$$cP45$$x1
000023050 588__ $$aDataset connected to Pubmed
000023050 7001_ $$0P:(DE-HGF)0$$aAnsaloni, A.$$b1
000023050 7001_ $$0P:(DE-HGF)0$$aVarisco, Y.$$b2
000023050 7001_ $$0P:(DE-HGF)0$$aJan, A.$$b3
000023050 7001_ $$0P:(DE-HGF)0$$aSreenivasachary, N.$$b4
000023050 7001_ $$0P:(DE-HGF)0$$aRezaei-Ghaleh, N.$$b5
000023050 7001_ $$0P:(DE-HGF)0$$aGiriens, V.$$b6
000023050 7001_ $$0P:(DE-HGF)0$$aLohmann, S.$$b7
000023050 7001_ $$0P:(DE-HGF)0$$aPilar López-Deber, M.$$b8
000023050 7001_ $$0P:(DE-HGF)0$$aAdolfsson, O.$$b9
000023050 7001_ $$0P:(DE-Juel1)VDB72755$$aPihlgren, M.$$b10$$uFZJ
000023050 7001_ $$0P:(DE-Juel1)VDB109265$$aPaganetti, P.$$b11$$uFZJ
000023050 7001_ $$0P:(DE-HGF)0$$aFroestl, W.$$b12
000023050 7001_ $$0P:(DE-Juel1)VDB72731$$aNagel-Steger, L.$$b13$$uFZJ
000023050 7001_ $$0P:(DE-Juel1)132029$$aWillbold, D$$b14$$uFZJ
000023050 7001_ $$0P:(DE-HGF)0$$aSchrader, T$$b15
000023050 7001_ $$0P:(DE-HGF)0$$aZweckstetter, M.$$b16
000023050 7001_ $$0P:(DE-HGF)0$$aPfeifer, A.$$b17
000023050 7001_ $$0P:(DE-HGF)0$$aLashuel, H.A.$$b18
000023050 7001_ $$0P:(DE-HGF)0$$aMuhs, A.$$b19
000023050 773__ $$0PERI:(DE-600)1474604-9$$a10.1074/jbc.M112.357665$$gVol. 287, p. 34786 - 34800$$p34786 - 34800$$q287<34786 - 34800$$tThe @journal of biological chemistry$$v287$$x0021-9258$$y2012
000023050 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464581
000023050 909CO $$ooai:juser.fz-juelich.de:23050$$pVDB
000023050 9141_ $$y2012
000023050 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000023050 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000023050 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000023050 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000023050 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000023050 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000023050 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000023050 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000023050 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000023050 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000023050 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000023050 9131_ $$0G:(DE-Juel1)FUEK409$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000023050 9131_ $$0G:(DE-Juel1)FUEK505$$1G:(DE-HGF)POF2-450$$2G:(DE-HGF)POF2-400$$bSchlüsseltechnologien$$kP45$$lBiologische Informationsverarbeitung$$vBioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung$$x1
000023050 9132_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lBioSoft  Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000023050 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$gICS$$kICS-6$$lStrukturbiochemie$$x0
000023050 970__ $$aVDB:(DE-Juel1)139941
000023050 980__ $$aVDB
000023050 980__ $$aConvertedRecord
000023050 980__ $$ajournal
000023050 980__ $$aI:(DE-Juel1)ICS-6-20110106
000023050 980__ $$aUNRESTRICTED
000023050 981__ $$aI:(DE-Juel1)IBI-7-20200312